GO:0001595 angiotensin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001595 angiotensin receptor activity is defined as combining with angiotensin to initiate a change in cell activity.
• Angiotensin II is the primary ligand for angiotensin receptors, and receptor activation triggers vasoconstriction, aldosterone release, and cellular growth responses.
• Two major receptor subtypes, AT1 and AT2, often mediate opposing effects in heart failure and hypertension.
• Receptor desensitization and internalization are key regulatory mechanisms that prevent overactivation.
• Angiotensin receptor-associated proteins locally modulate receptor function and downstream signaling.
• Angiotensin receptor-neprilysin inhibitors (ARNIs) combine receptor blockade with neprilysin inhibition and improve exercise parameters in heart failure [2,4,5,6].
Description
Angiotensin receptor activity (GO:0001595) is a molecular function that enables a cell to bind angiotensin peptides and convert that binding event into an intracellular signal. This activity is central to the renin-angiotensin system (RAS), a hormonal cascade that regulates blood pressure, fluid balance, and cardiovascular remodeling. The receptor acts as a transducer: when angiotensin II binds, the receptor changes conformation and activates heterotrimeric G proteins and other signaling effectors, ultimately altering cell behavior. Because RAS overactivity contributes to heart failure, hypertension, and arrhythmias, angiotensin receptors are among the most intensively studied drug targets in cardiovascular medicine [1,4,5]. Researchers investigating GO:0001595 need reliable models to dissect receptor signaling, desensitization, and crosstalk with associated proteins [7,8]. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of angiotensin receptor activity, its key genes, disease relevance, and experimental approaches.
angiotensin receptor activity At A Glance
| GO ID | GO:0001595 |
|---|---|
| GO term | angiotensin receptor activity |
| Ontology | molecular_function |
| Synonym | none listed in QuickGO |
| Major function | Binding angiotensin peptides and initiating intracellular signaling |
| Primary ligand | Angiotensin II |
| Major receptor subtypes | AT1 and AT2 |
| Associated regulation | Desensitization and internalization |
| Modulatory proteins | Angiotensin receptor-associated proteins |
What Is GO:0001595?
According to the Gene Ontology, GO:0001595 angiotensin receptor activity is defined as combining with angiotensin to initiate a change in cell activity. In practical terms, this means the receptor protein selectively binds angiotensin peptides (primarily angiotensin II) and, upon binding, undergoes a conformational change that propagates a signal inside the cell. This activity is distinct from angiotensin binding alone; it requires signal transduction leading to a measurable cellular response, such as contraction, secretion, or gene expression changes.
Why Is angiotensin receptor activity Important in Cell Biology?
Angiotensin receptor activity is a linchpin of cardiovascular homeostasis and disease. Overactivation of AT1 receptors promotes vasoconstriction, sodium retention, cardiac hypertrophy, and fibrosis, all of which contribute to heart failure and hypertension. Conversely, AT2 receptors can counterregulate these effects, and the balance between receptor subtypes influences disease progression. Pharmacological blockade of angiotensin receptors (ARBs) or combined angiotensin receptor-neprilysin inhibition (ARNIs) improves outcomes in heart failure with reduced ejection fraction and hypertension [2,4,5,6]. Understanding the molecular details of GO:0001595 is therefore essential for developing targeted therapies and for interpreting genetic and pharmacological studies [3,7,8].
• Regulates blood pressure and fluid balance through vasoconstriction and aldosterone release.
• Mediates cardiac hypertrophy and fibrosis in heart failure.
• AT1 and AT2 subtypes often exert opposing effects on cell growth and apoptosis.
• Receptor desensitization prevents chronic overactivation and is dysregulated in disease.
• Associated proteins fine-tune receptor trafficking and signaling specificity.
• Targeted by ARBs and ARNIs, which are mainstays of heart failure and hypertension therapy [2,4,5,6].
• Involved in arrhythmogenesis and electrical remodeling in the heart.
• Serves as a model for studying G protein-coupled receptor (GPCR) pharmacology.
• Genetic variants in receptor pathway genes influence drug responses.
• Provides a paradigm for understanding hormone-receptor feedback loops.
Molecular Mechanism of angiotensin receptor activity
Ligand Binding and Receptor Activation
In simple terms: Angiotensin II binds to the receptor like a key in a lock, causing the receptor to change shape and send a signal inside the cell.
Angiotensin receptor activity begins with the binding of angiotensin II to the extracellular domain of the receptor. This interaction is highly specific and triggers a conformational change in the receptor, which is a seven-transmembrane GPCR. The activated receptor then couples to heterotrimeric G proteins, leading to the exchange of GDP for GTP on the G-alpha subunit and dissociation of G-beta-gamma dimers. These events initiate downstream signaling cascades that alter cell activity.
G Protein-Dependent Signaling
In simple terms: Once activated, the receptor turns on G proteins, which then relay the signal to enzymes and ion channels.
The primary G protein-dependent pathway for AT1 receptors involves Gq/11, which activates phospholipase C-beta, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C. These second messengers drive cellular responses such as smooth muscle contraction, aldosterone secretion, and gene expression changes. AT2 receptors can couple to other G proteins or act through phosphatase pathways, often opposing AT1 effects.
Desensitization and Internalization
In simple terms: After signaling, the receptor is turned off and pulled inside the cell to prevent overstimulation.
Prolonged exposure to angiotensin II leads to desensitization of the receptor, a process that reduces its responsiveness. This involves phosphorylation of the receptor by G protein-coupled receptor kinases (GRKs), followed by binding of beta-arrestin, which uncouples the receptor from G proteins and promotes internalization. Internalized receptors can be recycled back to the plasma membrane or targeted for degradation, thereby modulating the duration and intensity of signaling.
Modulation by Receptor-Associated Proteins
In simple terms: Other proteins can bind to the receptor and tweak its activity, like accessories that change how a tool works.
Angiotensin receptor-associated proteins (ARAPs) interact with the receptor and locally modulate its function. These proteins can influence receptor trafficking, signaling efficiency, and crosstalk with other pathways. For example, some ARAPs enhance receptor internalization or alter downstream MAP kinase activation. This layer of regulation adds specificity and context-dependence to angiotensin receptor activity in different tissues.
Key Genes Involved in GO:0001595 angiotensin receptor activity
The following genes and proteins are central to angiotensin receptor activity, including receptors, ligands, and key signaling modulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGTR1 | AT1 receptor; mediates vasoconstriction, aldosterone release, and growth | Primary target of ARBs; knockout models show reduced blood pressure |
| AGTR2 | AT2 receptor; often opposes AT1 effects, promotes apoptosis and vasodilation | Knockout studies reveal counterregulatory roles in heart failure |
| AGT | Angiotensinogen; precursor of angiotensin peptides | Genetic variants linked to hypertension; knockout reduces RAS activity |
| REN | Renin; rate-limiting enzyme in angiotensin II production | Therapeutic target in hypertension; knockout models are hypotensive |
| ACE | Angiotensin-converting enzyme; generates angiotensin II | Target of ACE inhibitors; knockout alters blood pressure |
| ACE2 | Converts angiotensin II to angiotensin-(1-7) | Counterregulatory axis; knockout worsens cardiac dysfunction |
| AGTRAP | AT1 receptor-associated protein; modulates receptor trafficking | Regulates receptor internalization and signaling |
| ARAP1 | Angiotensin receptor-associated protein; affects receptor recycling | Influences AT1 signaling and cell growth |
| GRK2 | G protein-coupled receptor kinase; phosphorylates AT1 receptor | Mediates desensitization; knockout enhances receptor signaling |
| ARRB1 | Beta-arrestin 1; scaffolds receptor internalization | Biased agonism studies; knockout alters receptor trafficking |
| ARRB2 | Beta-arrestin 2; regulates receptor desensitization | Knockout models show prolonged signaling |
| GNAQ | Gq alpha subunit; couples AT1 to phospholipase C | Knockout reduces angiotensin II responses |
| GNA11 | G11 alpha subunit; alternative Gq/11 partner | Compensatory roles in AT1 signaling |
| PLCB1 | Phospholipase C beta 1; generates IP3 and DAG | Knockdown attenuates angiotensin II-induced calcium release |
| PRKCA | Protein kinase C alpha; downstream effector | Involved in hypertrophy; knockout reduces remodeling |
| NPPA | Atrial natriuretic peptide; counterregulates RAS | Biomarker in heart failure; knockout leads to hypertension |
| NPPB | B-type natriuretic peptide; opposes RAS effects | Used as heart failure biomarker; ARNI increases levels |
| NOS3 | Endothelial nitric oxide synthase; modulates vascular tone | AT2 receptor activation enhances NO production |
How Is angiotensin receptor activity Regulated?
Angiotensin receptor activity is tightly regulated at multiple levels. Desensitization via GRK-mediated phosphorylation and beta-arrestin recruitment reduces receptor responsiveness after prolonged agonist exposure. Receptor internalization and recycling control the number of surface receptors available for signaling. Angiotensin receptor-associated proteins (ARAPs) can locally modulate receptor trafficking and downstream signaling, adding tissue-specific regulation. Additionally, the renin-angiotensin system is subject to feedback regulation by angiotensin II itself, which suppresses renin release. These regulatory mechanisms prevent overactivation and maintain cardiovascular homeostasis [1,7,8].
angiotensin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGTR1 | Heart failure, hypertension | Cardiomyocyte-specific knockout or point mutation |
| AGTR2 | Counterregulation in heart failure | Knockout mouse with pressure overload |
| ACE2 | Cardiac dysfunction, RAS imbalance | Knock-in of human ACE2 variant |
| GRK2 | Desensitization defects in heart failure | Kinase-dead knock-in |
| AGTRAP | Altered receptor trafficking in hypertension | Overexpression or knockout in vascular smooth muscle |
Heart Failure
Enhanced angiotensin II activity and AT1 receptor signaling contribute to cardiac hypertrophy, fibrosis, and reduced ejection fraction in heart failure. AT2 receptors may counterregulate these effects, but the balance is often disrupted. Angiotensin receptor-neprilysin inhibitors (ARNIs) improve exercise parameters and physical activity in patients with heart failure with reduced ejection fraction [2,6]. ARNIs also reduce arrhythmias and improve hemodynamics in hypertensive heart disease [4,5].
Hypertension
Overactivation of AT1 receptors causes vasoconstriction and sodium retention, leading to elevated blood pressure. ARBs and ARNIs are effective antihypertensive agents that block angiotensin receptor activity. Genetic variants in AGTR1, AGT, and REN influence individual responses to these therapies.
Cardiac Arrhythmias
Angiotensin receptor signaling promotes electrical remodeling and fibrosis, creating a substrate for atrial and ventricular arrhythmias. ARNI therapy has been associated with reduced arrhythmia burden in heart failure patients. The interplay between AT1 and AT2 receptors modulates arrhythmogenesis [1,5].
From angiotensin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AT1 receptor mediate cardiac hypertrophy? | Cardiomyocyte-specific AGTR1 knockout |
| What is the role of AT2 receptor in counterregulation? | AGTR2 knockout mouse with angiotensin II infusion |
| How does GRK2 phosphorylation affect desensitization? | GRK2 point mutation (kinase-dead) knock-in |
| Does AGTRAP modulate receptor recycling? | AGTRAP tagged knock-in for live imaging |
| Can overexpression of ACE2 protect against heart failure? | ACE2 overexpression transgenic model |
| What is the effect of ARNI on exercise capacity? | Human clinical study with implantable device monitoring |
How to Study the angiotensin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor affinity and density | Characterizing AT1 vs AT2 pharmacology |
| Calcium imaging | Intracellular calcium release | Gq-coupled signaling |
| IP3 assay | Phospholipase C activity | Downstream second messenger |
| Immunofluorescence | Receptor localization and internalization | Desensitization studies |
| Western blot | Phosphorylation of GRK2 or receptor | Desensitization mechanism |
| CRISPR knockout | Gene function loss | Validating receptor subtypes |
| RNA-seq | Transcriptional changes | Angiotensin II-induced gene expression |
| Proteomics | Protein interactions | Identifying receptor-associated proteins |
Ligand Binding Assays
Radioligand binding assays using iodine-125-labeled angiotensin II measure receptor affinity, density, and competition by antagonists. These assays are foundational for characterizing angiotensin receptor activity and testing novel ligands.
Signal Transduction Assays
Calcium mobilization, IP3 accumulation, and reporter gene assays quantify downstream signaling after receptor activation. These methods are used to dissect G protein-dependent and independent pathways.
Desensitization and Internalization Studies
Receptor internalization can be measured by flow cytometry or immunofluorescence using tagged receptors. GRK-mediated phosphorylation is assessed by immunoprecipitation and phospho-specific antibodies.
Genetic and Pharmacological Manipulation
Knockout mice, siRNA, and CRISPR-Cas9 editing enable loss-of-function studies for AGTR1, AGTR2, and associated genes [1,8]. Pharmacological tools include ARBs and ARNIs [2,4].
How CRISPR Can Be Used to Study GO:0001595 angiotensin receptor activity
Knockout
CRISPR-Cas9 knockout of AGTR1 or AGTR2 in cell lines or animal models abolishes receptor expression, allowing researchers to determine the specific contribution of each subtype to angiotensin II responses. Knockout of downstream effectors like GNAQ or PLCB1 can dissect signaling branches.
Point Mutation
Point mutations can be introduced into the AGTR1 gene to disrupt G protein coupling or GRK phosphorylation sites, enabling precise mapping of signaling and desensitization domains. For example, mutation of serine/threonine residues in the C-terminus prevents beta-arrestin recruitment.
Knock-in
Knock-in of tagged receptors (e.g., HA or GFP) allows live-cell imaging and biochemical purification of receptor complexes. Knock-in of human AGTR1 variants can model genetic differences in drug response.
Overexpression
Overexpression of AGTR1 or AGTR2 in cell lines or transgenic animals enhances receptor signaling and can model gain-of-function states in heart failure. Overexpression of ACE2 can shift the RAS balance toward the counterregulatory axis.
How EDITGENE Supports angiotensin receptor activity Research
Researchers studying angiotensin receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, desensitization, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for angiotensin receptor activity research.
Frequently Asked Questions About angiotensin receptor activity
What is angiotensin receptor activity?
Angiotensin receptor activity (GO:0001595) is the molecular function of combining with angiotensin peptides to initiate a change in cell activity, such as vasoconstriction or aldosterone release.
What genes are involved in angiotensin receptor activity?
Key genes include AGTR1 and AGTR2 (receptors), AGT, REN, ACE (ligand production), and GRK2, ARRB1, ARRB2 (desensitization) [1,7].
What is the difference between AT1 and AT2 receptors?
AT1 receptors typically mediate vasoconstriction, growth, and fibrosis, while AT2 receptors often oppose these effects, promoting vasodilation and apoptosis.
How is angiotensin receptor activity regulated?
It is regulated by desensitization via GRK-mediated phosphorylation and beta-arrestin recruitment, internalization, and receptor-associated proteins [7,8].
What diseases are linked to angiotensin receptor activity?
Heart failure, hypertension, and cardiac arrhythmias are major diseases linked to overactive angiotensin receptor signaling [1,4,5].
What are ARNIs and how do they work?
Angiotensin receptor-neprilysin inhibitors (ARNIs) combine an ARB with a neprilysin inhibitor, blocking AT1 receptors while increasing natriuretic peptides, improving heart failure outcomes [2,4,5,6].
How can I study angiotensin receptor activity in the lab?
Common methods include radioligand binding, calcium imaging, IP3 assays, and CRISPR knockout of receptor genes [3,1].
What is receptor desensitization?
Desensitization is the process by which prolonged agonist exposure reduces receptor responsiveness, often via GRK phosphorylation and beta-arrestin binding.
Can CRISPR be used to study angiotensin receptors?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect receptor function and signaling [1,7,8].
What are angiotensin receptor-associated proteins?
These are proteins that interact with angiotensin receptors and modulate their trafficking, signaling, and degradation, such as AGTRAP and ARAP1.
Conclusion
Angiotensin receptor activity (GO:0001595) is a fundamental molecular function that governs cardiovascular physiology and disease. Its definition, combining with angiotensin to initiate cellular changes, underscores its role as a signal transducer. The interplay between AT1 and AT2 receptors, along with desensitization mechanisms and associated proteins, determines the net effect of RAS activation [1,7,8]. Targeting this activity with ARBs and ARNIs has proven clinical benefit in heart failure and hypertension [2,4,5,6]. Continued research using CRISPR models and advanced assays will further illuminate the nuances of angiotensin receptor biology and guide new therapeutic strategies.
References
- 1. Opie LH et al.. 2001. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes.. Circ Res 88(7):654-8 PMID: 11304486
- 2. Volis I et al.. 2024. Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring.. J Cardiovasc Med (Hagerstown) 25(3):193-199 PMID: 38251452
- 3. Bumpus FM. 1977. Mechanisms and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor.. Fed Proc 36(8):2128-32 PMID: 194800
- 4. Kario K et al.. 2022. Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease.. Hypertens Res 45(7):1097-1110 PMID: 35501475
- 5. Sutanto H et al.. 2021. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.. Int J Mol Sci 22(16) PMID: 34445698
- 6. Schwartzmann P. 2020. Angiotensin Receptor-Neprilysin Inhibition Therapy and Improved Exercise Parameters in Heart Failure with Reduced Ejection Fraction.. Arq Bras Cardiol 115(5):828-829 PMID: 33295444
- 7. Sasamura H et al.. 1994. Desensitization of angiotensin receptor function.. Kidney Int 46(6):1499-501 PMID: 7699989
- 8. Castrop H. 2013. Angiotensin receptor-associated proteins: local modulators of the renin-angiotensin system.. Pflugers Arch 465(1):111-9 PMID: 22588461
